Gynecologic Cancer

A novel antibody drug conjugate was granted a Fast Track designation for certain patients with ovarian cancer.

The Food and Drug Administration approved Udenyca Onbody, an administration device for Udenyca, a biosimilar of Neulasta.

A treatment combination of avutometinib and defactinib is being evaluated in a new phase 3 trial for patients with low-grade serous ovarian cancer.

Cervical cancer survival and Cervivor ambassador Kate Weissman provides advice on conversations patients with cervical cancer should be having with their care teams.

A phase 3 trial demonstrated progression-free survival improvements with Tecentriq-chemotherapy combination in patients with endometrial carcinoma.

CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.

The addition of Keytruda to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

Platinum-based chemotherapy, when administered before chemoradiotherapy, improved progression-free and overall survival for patients with locally advanced cervical cancer.

Information about gynecologic cancers found on TikTok may not be credible or reliable, according to findings from a recent study.

The overexpression of the gene, BRD4, may be the cause of chemotherapy resistance in patients with high-grade serous ovarian cancer, according to research.

The FDA granted a priority review for a new supplemental Biologics License Application to Keytruda plus concurrent chemoradiotherapy for patients with locally advanced cervical cancer.

Rachelle’s unexpected departure reminded me I need to express my appreciation to these special, beloved providers now.

I always enjoyed writing about my summers, but this is what I would write today.

I faced cancer thrice and chose life each time — not because of some flowery will to live, but because I’m stubborn and wanted to prove that cancer is not the boss of me.

Here’s a look back at the therapies for solid cancers that gained FDA approval this summer.

While the recent approval of a Jemperli-based regimen was an exciting advancement in the endometrial cancer space, racial disparities still exist and need to be addressed, and expert said.

Jemperli plus chemotherapy has been approved for the treatment of adults with primary advanced or recurrent mismatch repair deficient (dMMR) or microsatellite instability-high endometrial cancer.

High-level results from a phase 3 trial demonstrated that treatment with batiraxcept did not improve progression-free survival in patients with platinum-resistant ovarian cancer.

The Food and Drug Administration approved Jemperli with chemotherapy and then alone for patients with dMMR or MSI-H advanced endometrial cancer.

Patients with HER2-expressing cancers using Enhertu saw significant improvements in progression-free survival and overall survival.

We recently asked our audience of patients, survivors and caregivers about the ongoing cisplatin and carboplatin shortage. Here’s what they had to say.

Adding Keytruda to chemoradiotherapy significantly improved progression-free survival for patients with newly diagnosed high-risk locally advanced cervical cancer.

While inflammation may not be associated with certain cancer-related symptoms, it can impact depression and physical activity levels in anyone, recent research showed.

The final overall survival results of the PAOLA-1/ENGOT-ov25 trial confirmed the drug combination as “one of the standards of care” for some populations of patients with ovarian cancer.